Treatment Extent of Femoropopliteal Disease and Clinical Outcomes Following Endovascular Therapy

Overview

Journal EuroIntervention

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2024 Sep 16

PMID 39279516

Authors

Yong-Hoon Yoon

Jae-Hwan Lee

Won-Mook Hwang

Hyun-Woong Park

Jae-Hyung Roh

Seung-Jun Lee

Young-Guk Ko

Chul-Min Ahn

Cheol Woong Yu

Seung-Whan Lee

Young Jin Youn

Jong Kwan Park

Chang-Hwan Yoon

Seung-Woon Rha

Pil-Ki Min

Seung-Hyuk Choi

In-Ho Chae

Donghoon Choi

Of The K-Vis Investigators On Behalf

Affiliations

Soon will be listed here.

Abstract

Background: Endovascular therapy (EVT) has become the preferred treatment modality for femoropopliteal disease. However, there is limited evidence regarding its procedural and clinical outcomes according to the affected area.

Aims: The aim of this study is to investigate clinical outcomes and device effectiveness according to treatment extent in the superficial femoral artery (SFA), popliteal artery (PA), or both.

Methods: In this study, we analysed EVT for SFA (2,404 limbs), PA (155 limbs), SFA/PA (383 limbs) using the population in the K-VIS ELLA (Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases) registry. The primary endpoint was target lesion revascularisation (TLR) at 2 years.

Results: The SFA/PA group exhibited a higher prevalence of anatomical complexity, characterised by long lesions, moderate to severe calcification, and total occlusion. The procedures were successful in 97.2% of SFA, 92.9% of PA, and 95.6% of SFA/PA EVTs. The 2-year TLR rates were 21.1%, 18.6%, and 32.7% in the SFA, PA, and SFA/PA groups, respectively. SFA/PA EVT was associated with a significantly increased risk for TLR compared to the SFA group (adjusted hazard ratio [HR] 1.48 [1.09-2.00]; p=0.008) and a trend towards an increased risk compared to the PA group (adjusted HR 1.80 [1.00-3.27]; p=0.052). After overlap weighting, the use of a drug-coated balloon (DCB) was shown to be beneficial, with the lowest TLR rate after SFA and SFA/PA EVT.

Conclusions: In this large real-world registry, SFA/PA EVT was associated with an increased risk for TLR at 2 years compared to the SFA or PA EVT groups, with favourable outcomes when using a DCB or drug-eluting stent in the SFA/PA EVT group.

References

Aday A, Matsushita K . Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circ Res. 2021; 128(12):1818-1832. PMC: 8202714. DOI: 10.1161/CIRCRESAHA.121.318535. View

Aboyans V, Ricco J, Bartelink M, Bjorck M, Brodmann M, Cohnert T . 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric,.... Eur Heart J. 2017; 39(9):763-816. DOI: 10.1093/eurheartj/ehx095. View

Semaan E, Hamburg N, Nasr W, Shaw P, Eberhardt R, Woodson J . Endovascular management of the popliteal artery: comparison of atherectomy and angioplasty. Vasc Endovascular Surg. 2009; 44(1):25-31. PMC: 4429911. DOI: 10.1177/1538574409345028. View

Rastan A, McKinsey J, Garcia L, Rocha-Singh K, Jaff M, Noory E . One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions: Subgroup Results of the Prospective, Multicenter DEFINITIVE LE Trial. J Endovasc Ther. 2015; 22(6):839-46. DOI: 10.1177/1526602815608610. View

Liistro F, Angioli P, Porto I, Ducci K, Falsini G, Ventoruzzo G . Drug-Eluting Balloon Versus Drug-Eluting Stent for Complex Femoropopliteal Arterial Lesions: The DRASTICO Study. J Am Coll Cardiol. 2019; 74(2):205-215. DOI: 10.1016/j.jacc.2019.04.057. View

Bausback Y, Wittig T, Schmidt A, Zeller T, Bosiers M, Peeters P . Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease. J Am Coll Cardiol. 2019; 73(6):667-679. DOI: 10.1016/j.jacc.2018.11.039. View

Thieme M, von Bilderling P, Paetzel C, Karnabatidis D, Delgado J, Lichtenberg M . The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon. JACC Cardiovasc Interv. 2017; 10(16):1682-1690. DOI: 10.1016/j.jcin.2017.04.041. View

Rocha-Singh K, Zeller T, Jaff M . Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014; 83(6):E212-20. PMC: 4262070. DOI: 10.1002/ccd.25387. View

Zeller T, Brodmann M, Ansel G, Scheinert D, Choi D, Tepe G . Paclitaxel-coated balloons for femoropopliteal peripheral arterial disease: final five-year results of the IN.PACT Global Study. EuroIntervention. 2022; 18(11):e940-e948. PMC: 9743239. DOI: 10.4244/EIJ-D-21-01098. View

10.

Thomas L, Li F . Addressing Extreme Propensity Scores via the Overlap Weights. Am J Epidemiol. 2018; 188(1):250-257. DOI: 10.1093/aje/kwy201. View

11.

Altin S, Parise H, Hess C, Rosenthal N, Creager M, Aronow H . Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication. JACC Cardiovasc Interv. 2023; 16(13):1668-1678. DOI: 10.1016/j.jcin.2023.05.001. View

12.

Torsello G, Stavroulakis K, Brodmann M, Micari A, Tepe G, Veroux P . Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. J Endovasc Ther. 2020; 27(5):693-705. PMC: 7545651. DOI: 10.1177/1526602820931477. View

13.

Yoshioka N, Tokuda T, Koyama A, Yamada T, Nishikawa R, Shimamura K . Clinical outcomes and predictors of restenosis in patients with femoropopliteal artery disease treated using polymer-coated paclitaxel-eluting stents or drug-coated balloons. Heart Vessels. 2021; 37(4):555-566. DOI: 10.1007/s00380-021-01941-9. View

14.

Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M . Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials. JACC Cardiovasc Interv. 2016; 9(16):1731-42. DOI: 10.1016/j.jcin.2016.06.008. View

15.

Lee S, Lee H, Ko Y, Ahn C, Lee Y, Kim J . Device Effectiveness for Femoropopliteal Artery Disease Treatment: An Analysis of K-VIS ELLA Registry. JACC Cardiovasc Interv. 2023; 16(13):1640-1650. DOI: 10.1016/j.jcin.2023.05.002. View

16.

Kroger K, Santosa F, Goyen M . Biomechanical incompatibility of popliteal stent placement. J Endovasc Ther. 2004; 11(6):686-94. DOI: 10.1583/04-127.1. View

17.

Scheinert D, Werner M, Scheinert S, Paetzold A, Banning-Eichenseer U, Piorkowski M . Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv. 2013; 6(1):65-71. DOI: 10.1016/j.jcin.2012.09.011. View

18.

Rastan A, Krankenberg H, Baumgartner I, Blessing E, Muller-Hulsbeck S, Pilger E . Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. Circulation. 2013; 127(25):2535-41. DOI: 10.1161/CIRCULATIONAHA.113.001849. View

19.

Jadidi M, Razian S, Anttila E, Doan T, Adamson J, Pipinos M . Comparison of morphometric, structural, mechanical, and physiologic characteristics of human superficial femoral and popliteal arteries. Acta Biomater. 2020; 121:431-443. PMC: 7855696. DOI: 10.1016/j.actbio.2020.11.025. View

20.

Stavroulakis K, Schwindt A, Torsello G, Stachmann A, Hericks C, Bosiers M . Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions. J Endovasc Ther. 2016; 24(2):181-188. DOI: 10.1177/1526602816683933. View